COGT net incomeQ3 2026-$111.43M
COGT net income was -$111.43M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$80.93M a year earlier. For the full fiscal 2025 it was -$328.94M, compared with -$255.86M in fiscal 2024.
Cogent Biosciences Inc. (COGT) financials
For the twelve months ended Sep 30, 2026, Cogent Biosciences Inc. reported -$407.68M of net income.
- Net income, TTM
- -$407.68M
- Free cash flow, TTM
- -$325.78M
- EPS, diluted, TTM
- -$2.25
- Cash
- $217.46M
- Total debt
- $223.74M
- Market cap
- $5.49B
FY2017FY2020
FY2017FY2025
FY2017FY2025
COGT revenue and earnings growth
COGT EPSQ3 2026-$0.59
COGT diluted EPS was -$0.59 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.50 a year earlier. For the full fiscal 2025 it was -$2.16, compared with -$1.94 in fiscal 2024.
COGT free cash flowQ3 2026-$80.89M
COGT free cash flow was -$80.89M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$64.35M a year earlier. For the full fiscal 2025 it was -$266.00M, compared with -$208.36M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $7.87M | $22.50M | $9.73M | $8.36M |
| Research and development | $269.78M | $232.66M | $173.75M | $121.63M | $55.91M | $25.74M | $43.71M | $38.28M | $29.83M |
| Selling, general and admin | $63.58M | $43.28M | $34.38M | $26.21M | $19.64M | $17.42M | $10.97M | $7.45M | $4.68M |
| Operating income | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -$75.55M | -$82.20M | -$32.18M | -$36.01M | -$26.15M |
| Interest expense | $3.06M | - | - | - | - | - | - | - | - |
| Income tax | $0 | - | - | - | - | - | - | - | - |
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -$72.27M | -$74.81M | -$31.83M | -$34.53M | -$25.49M |
| EPS, basic | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | -$16.17 | -$4.18 | -$5.56 | -$10.04 |
| EPS, diluted | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | -$16.17 | -$4.18 | -$5.56 | -$10.04 |
| Diluted shares | 128.9M | 103.9M | 79.7M | 58.7M | 38.7M | 11.1M | 7.6M | 6.2M | 2.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $312.01M | $98.17M | $53.23M | $141.14M | $220.94M | $243.44M | $38.68M | $56.93M | $29.60M |
| Short-term investments | - | - | - | - | - | - | - | - | $12.69M |
| Receivables | - | - | - | - | - | - | $2.00M | $1.67M | $830.0K |
| Current assets | $910.36M | $296.47M | $270.77M | $264.97M | $222.63M | $244.91M | $40.59M | $81.00M | $42.38M |
| Total assets | $937.61M | $327.90M | $313.44M | $300.81M | $232.09M | $250.92M | $49.42M | $85.93M | $49.12M |
| Current liabilities | $63.95M | $55.71M | $38.17M | $26.85M | $17.08M | $13.09M | $13.25M | $24.95M | $11.19M |
| Long-term debt | - | $0 | - | - | - | - | - | - | - |
| Total debt | $222.90M | $0 | - | - | - | - | - | - | - |
| Total liabilities | $301.24M | $71.61M | $55.63M | $45.08M | $17.91M | $16.25M | $17.66M | $25.69M | $20.81M |
| Shareholders' equity | $636.37M | $256.29M | $257.80M | $255.74M | $214.18M | $234.67M | $31.76M | $60.23M | -$48.85M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$264.44M | -$207.79M | -$153.62M | -$118.64M | -$58.76M | -$35.85M | -$41.51M | -$32.49M | -$25.84M |
| Capital expenditures | $1.55M | $573.0K | $2.80M | $6.86M | $1.72M | - | $33.0K | $549.0K | $912.0K |
| Free cash flow | -$266.00M | -$208.36M | -$156.42M | -$125.50M | -$60.48M | - | -$41.55M | -$33.04M | -$26.75M |
| Investing cash flow | -$399.53M | $38.28M | -$97.82M | -$124.72M | -$1.72M | $8.42M | $23.16M | -$10.53M | $13.59M |
| Financing cash flow | $878.23M | $214.45M | $163.54M | $163.56M | $37.98M | $232.20M | $108.0K | $70.35M | -$729.0K |
| Stock-based compensation | $46.08M | $39.74M | $30.62M | $18.37M | $11.69M | $6.02M | $3.24M | $3.09M | $1.34M |
| Depreciation and amortization | $2.60M | $2.50M | $2.30M | $800.0K | $147.0K | $720.0K | $1.29M | $1.32M | $1.17M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | -65.0% | 131.1% | 16.4% | - |
| Operating margin | - | - | - | - | - | -1044.3% | -143.0% | -369.9% | -312.8% |
| Net margin | - | - | - | - | - | -950.4% | -141.5% | -354.8% | -304.9% |
| Free cash flow margin | - | - | - | - | - | - | -184.7% | -339.4% | -319.9% |
| Return on equity | -51.7% | -99.8% | -74.6% | -54.8% | -33.7% | -31.9% | -100.2% | -57.3% | - |
| Return on assets | -35.1% | -78.0% | -61.4% | -46.6% | -31.1% | -29.8% | -64.4% | -40.2% | -51.9% |
| Current ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 |
| Debt to equity | 0.35 | 0.00 | - | - | - | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $75.10M | $70.81M | $75.36M | $75.56M | $68.99M | $62.20M | $63.03M | $62.05M | $63.61M | $54.29M | $52.70M | $48.72M |
| Selling, general and admin | $42.09M | $31.83M | $28.24M | $23.93M | $14.37M | $13.38M | $11.90M | $11.69M | $11.80M | $10.09M | $9.70M | $9.51M |
| Operating income | -$117.18M | -$102.64M | -$103.61M | -$99.49M | -$83.36M | -$75.58M | -$74.93M | -$73.73M | -$75.41M | -$64.39M | -$62.40M | -$58.23M |
| Interest expense | $1.24M | $1.22M | $1.21M | $1.29M | $1.46M | $314.0K | $0 | - | - | - | - | - |
| Net income | -$111.43M | -$96.41M | -$97.35M | -$102.49M | -$80.93M | -$73.53M | -$71.99M | -$67.93M | -$70.63M | -$58.95M | -$58.35M | -$54.37M |
| EPS, basic | -$0.59 | -$0.52 | -$0.53 | -$0.61 | -$0.50 | -$0.53 | -$0.52 | -$0.50 | -$0.52 | -$0.43 | -$0.49 | -$0.16 |
| EPS, diluted | -$0.59 | -$0.52 | -$0.53 | -$0.61 | -$0.50 | -$0.53 | -$0.52 | -$0.50 | -$0.52 | -$0.43 | -$0.49 | -$0.16 |
| Diluted shares | 173.1M | 171.0M | 162.2M | - | 137.6M | 114.5M | 113.3M | - | 110.2M | 99.2M | 94.8M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $217.46M | $181.17M | $241.21M | $312.01M | $125.63M | $127.60M | $126.00M | $98.17M | $97.05M | $88.22M | $215.80M | $53.23M |
| Current assets | $803.58M | $804.82M | $877.80M | $910.36M | $397.24M | $245.01M | $252.88M | $296.47M | $341.53M | $369.97M | $441.90M | $270.77M |
| Total assets | $832.14M | $834.55M | $903.01M | $937.61M | $425.93M | $274.82M | $283.80M | $327.90M | $384.02M | $429.94M | $476.11M | $313.44M |
| Current liabilities | $73.12M | $59.30M | $57.98M | $63.95M | $62.25M | $58.42M | $49.32M | $55.71M | $53.05M | $40.00M | $36.69M | $38.17M |
| Long-term debt | - | - | - | - | $44.25M | $43.95M | - | $0 | - | - | - | - |
| Total debt | $223.74M | $223.46M | $223.17M | $222.90M | $44.25M | $43.95M | - | $0 | - | - | - | - |
| Total liabilities | $315.88M | $302.16M | $295.31M | $301.24M | $123.47M | $119.78M | $64.80M | $71.61M | $69.36M | $56.71M | $53.78M | $55.63M |
| Shareholders' equity | $516.26M | $532.39M | $607.69M | $636.37M | $302.46M | $155.04M | $219.00M | $256.29M | $314.66M | $373.22M | $422.33M | $257.80M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$80.79M | -$77.27M | -$86.88M | -$79.11M | -$64.29M | -$54.54M | -$66.51M | -$60.58M | -$51.98M | -$42.70M | -$52.53M | -$44.07M |
| Capital expenditures | $108.0K | $370.0K | $449.0K | $811.0K | $65.0K | $131.0K | $547.0K | $75.0K | $280.0K | $148.0K | $70.0K | $315.0K |
| Free cash flow | -$80.89M | -$77.64M | -$87.33M | -$79.92M | -$64.35M | -$54.67M | -$67.06M | -$60.65M | -$52.26M | -$42.85M | -$52.60M | -$44.38M |
| Investing cash flow | $37.31M | $14.28M | -$36.46M | -$322.77M | -$155.05M | $8.91M | $69.38M | $61.67M | $60.19M | -$84.63M | $1.04M | $10.49M |
| Financing cash flow | $79.76M | $2.96M | $52.54M | $588.67M | $217.37M | $47.23M | $24.97M | $26.0K | $624.0K | -$256.0K | $214.06M | $0 |
| Stock-based compensation | $16.87M | $17.11M | $16.91M | $15.75M | $10.60M | $9.72M | $10.01M | $9.98M | $10.36M | $10.01M | $9.39M | $8.85M |
| Depreciation and amortization | $572.0K | $741.0K | $626.0K | $664.0K | $641.0K | $655.0K | $640.0K | $675.0K | $620.0K | $606.0K | $599.0K | $628.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 10.99 | 13.57 | 15.14 | 14.23 | 6.38 | 4.19 | 5.13 | 5.32 | 6.44 | 9.25 | 12.05 | 7.09 |
| Debt to equity | 0.43 | 0.42 | 0.37 | 0.35 | 0.15 | 0.28 | - | 0.00 | - | - | - | - |
Source: XBRL data Cogent Biosciences Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-4, first reported Nov 9, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
COGT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| COGT | - | - | -$407.68M | - | $5.49B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
COGT FAQ
6 questionsIs COGT profitable?
No. Cogent Biosciences Inc. reported a net loss of $407.68M for the twelve months ended Sep 30, 2026.How much cash and debt does COGT have?
Cogent Biosciences Inc. reported $217.46M in cash and cash equivalents and $223.74M of debt on its most recent balance sheet in SEC filings.What is COGT free cash flow?
Cogent Biosciences Inc. generated -$325.78M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$324.05M less capital expenditures.What is COGT earnings per share?
Diluted earnings per share were -$2.25 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did COGT last report financial results?
The latest statements here come from Cogent Biosciences Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this COGT financial data come from?
Quantisnow builds these statements from the structured XBRL data Cogent Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.